Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Blood (2019) 134 (Supplement_1): 1656.

https://doi.org/10.1182/blood-2019-130691

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs

Blood (2019) 134 (Supplement_1): 3044.

https://doi.org/10.1182/blood-2019-125530

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Blood (2019) 134 (Supplement_1): 4114.

https://doi.org/10.1182/blood-2019-128298

Published: 2019

Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 4309.

https://doi.org/10.1182/blood-2019-128645

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Vladimir I. Vorobyev, MD PhD, Vera A. Zherebtsova, MD PhD, Egor I. Dubrovin, Liudmila A. Bychenkova, Lev S. Butaev, Larisa A. Muha, Yulia B. Kochkareva, Valentina L. Ivanova, Eugene A. Nikitin, MD PhD Professor, Gayane Tumyan, DMSc, MD PhD, Vadim A Doronin, MD, Oleg I. Krijanovski, MD PhD, Vadim Ptushkin, MD PhD Professor

Blood (2019) 134 (Supplement_1): 5255.

https://doi.org/10.1182/blood-2019-126430

Published: 2019

Journal Articles

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Lin Gu, MS, Guan Xing, PhD, Nishan Rajakumaraswamy, MD, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5468.

https://doi.org/10.1182/blood-2019-124541

Published: 2019

Journal Articles

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Galina Salogub, MD PhD, Jiri Mayer, MD, Frantisek Folber, MD PhD, Sebastian Grosicki, MD PhD, Aleksander B Skotnicki, MD PhD, Anna Prochwicz, MD, Alexander Myasnikov, MD, Alexander Gural, MD, Oliver Schoenborn-Kellenberger, MSc, Charlie Brindley, PhD, Stefan Knackmuss, PhD, Sylvia Schwarz, PhD, Sandra Schmich, Cassandra Choe-Juliak, MD MS, Andras Strassz, MD, Leila Alland, MD, Michael Doubek, MD PhD

Blood (2018) 132 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2018-99-118136

Published: 2018

Journal Articles

Type 1 Gaucher Disease Severity and Risk for Liver Fibrosis in Untreated Patients and in Patients Treated Primarily with Enzyme Replacement Therapy for a Median of 20 Years

Neal J Weinreb, MD, Robert A Ali, MD

Blood (2018) 132 (Supplement 1): 2403.

https://doi.org/10.1182/blood-2018-99-117215

Published: 2018

Journal Articles

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Selina J Chavda, MBBS, BSc, MRCP, Rachael Pocock, MBBS, BSc, MRCP, Simon Cheesman, BPharm, Emma Dowling, Puneet Verma, MRPharmS, Malcolm Walker, MBBS, MBChB, MD FRCP, Charalampia Kyriakou, MD PhD, Ashutosh D. Wechalekar, Neil K Rabin, MD, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2018-99-113832

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

Journal Articles

A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

Jessica Choudhry, PharmD, RPh, Mandy Parson, BSN, Jacqueline Wright

Blood (2018) 132 (Supplement 1): 5211.

https://doi.org/10.1182/blood-2018-99-117353

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 5345.

https://doi.org/10.1182/blood-2018-99-113117

Published: 2018

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe

Blood (2018) 132 (Supplement 1): 703.

https://doi.org/10.1182/blood-2018-99-113776

Published: 2018

Journal Articles

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Akiko Mita, MD, Maiko Abumiya, PhD, Saori Takahashi, Ms, Yoshihiro Kameoka, MD PhD, Masatomo Miura, PhD, Naoto Takahashi, MD

Blood (2018) 132 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2018-99-111905

Published: 2018

Journal Articles

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher R Flowers, MD MS, Jonathon B. Cohen, MD MS, Susan Blumel, RN, Kathy Cutter, RN, Emily K. Pauli, BMBS,PharmD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2018-99-118917

Published: 2018

NARROW

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Type 1 Gaucher Disease Severity and Risk for Liver Fibrosis in Untreated Patients and in Patients Treated Primarily with Enzyme Replacement Therapy for a Median of 20 Years

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only